Product Program year 2023 Source: CMS Open Payments

Katerzia

Drug pediatric hypertension

NDC 52652-5001-1

Open in the dashboard

General payments

$34,518

231 payments

Research payments

$0

0 payments

Through program year 2023, $34,518 in general payments and $0 in research payments were reported against Katerzia (pediatric hypertension).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2023 General $873 40
2022 General $537 30
2021 General $31,029 56
2020 General $1,567 83
2019 General $512 22

Breakdown

Who paid General payments · program years 2019–2023
  1. CutisPharma, Inc. $33,368 175 payments
  2. Silvergate Pharmaceuticals, Inc. $1,150 56 payments
Top recipients General payments · program year 2023
  1. Irene Restaino Pediatric Nephrology · Norfolk, VA $96 11% · 1 payment
  2. Obioma Nwobi Pediatric Nephrology · Miami, FL $52 6% · 2 payments
  3. Nicole Christin Pediatric Nephrology · Miami, FL $52 6% · 2 payments
  4. Carolina Marquez Nurse Practitioner, Pediatrics · Miami, FL $52 6% · 2 payments
  5. Lennis Burke Pediatric Cardiology · Pasadena, CA $29 3% · 1 payment

The top 5 of 37 recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Pediatric Nephrology Pediatrics $395 45% · 13 practitioners
  2. Pediatric Cardiology Pediatrics $201 23% · 10 practitioners
  3. Nurse Practitioner, Pediatrics Nurse Practitioner $82 9% · 3 practitioners
  4. Pediatrics $50 6% · 3 practitioners
  5. Nurse Practitioner, Pediatrics, Critical Care Nurse Practitioner $20 2% · 1 practitioner

The top 5 of 12 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. California $215 25% · 11 recipients
  2. Florida $204 23% · 5 recipients
  3. Louisiana $130 15% · 7 recipients
  4. Virginia $110 13% · 2 recipients
  5. Texas $76 9% · 4 recipients

The top 5 of 10 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

519

Prescriptions dispensed, refills included

Drug cost

$436,490

Paid at the pharmacy, in all

Prescribers

39

With 11 or more claims of it

Medicare Part D drugs matched to Katerzia, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Katerzia Amlodipine Benzoate Same name 39 519 $436,490

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 39 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Karla Willson Nurse Practitioner MI 25 $7,894 No profile
Katherine Gruenkemeyer Nurse Practitioner MO 23 $10,662 None on record
Randa Razzouk Nephrology TX 20 $13,433 None on record
Reem Raafat Pediatric Medicine FL 17 $14,937 None on record
Oluwadamilola Ejike Pediatric Medicine FL 16 $18,818 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 39 with Patron
231 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record